483
Bora Pharmaceuticals Injectables IncBora Pharmaceuticals Injectables Inc – FDA 483, Aug 27, 2010
Record Details
An FDA inspection of Cangene bioPharma Inc. in Baltimore, MD, revealed significant deficiencies in quality assurance, aseptic processing, and facility maintenance. The firm failed to thoroughly investigate product discrepancies, maintain adequate visual inspection programs, and ensure proper material segregation and preventative maintenance for critical systems. These issues indicate a lack of robust controls over manufacturing processes and product quality.
View Company Profile
ID · 053d423a-ee3b-4474-95eb-e7981f3b1e37
Other documents for Bora Pharmaceuticals Injectables Inc
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.